Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

situximab

- PMLiVE

Janssen files Tremfya for psoriatic arthritis in Europe

Hopes to extend use beyond plaque psoriasis

- PMLiVE

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

Initially received a negative opinion of the drug

- PMLiVE

Merck wins CHMP recommendation for Ebola vaccine

Has also been granted priority review by FDA

- PMLiVE

Astellas’ Xospata scores positive CHMP recommendation

Could become a potential option for hard-to-treat leukaemia

- PMLiVE

FDA starts speedy review of Merck’s Ebola vaccine

First company to file for approval in the US

- PMLiVE

Imbruvica gains expanded use in Europe

Rival Calquence receives accelerated review in US

- PMLiVE

Trial backs role for Lynparza in second-line prostate cancer

Demonstrates potential significant benefit in treatment of disease

- PMLiVE

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

GW Pharma’s Epidyolex also on the recommended list

- PMLiVE

ViiV bags EU okay for new two-drug HIV therapy

Rivals Gilead's Biktarvy

- PMLiVE

CHMP blocks UCB/Amgen’s Evenity approval for osteoporosis

Another obstacle for drug

- PMLiVE

Merck says it has plenty in the pipe beyond Keytruda

It has the firepower, but is Merck seeking a big deal?

- PMLiVE

Merck & Co adds to immunotherapy again with $773m Tilos buy

Specialises in TGFβ complex-targeting therapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links